In preclinical models with mutations in three or the four of the pathways described, prominent T-cell exclusion and elevated TGF-β activity were demonstrated and the use of Galunisertib, a potent and selective TGF-β receptor I kinase inhibitor, reduced tumor size and prevented the appearance of liver metastases [146]. Here, TGFB1 is linked to neoplasm.